The path forward for Gilead Sciences, Inc.’s filgotinib looks increasingly uncertain as the company weighs strategies following a surprise rejection over the summer by the US Food and Drug Administration. During Gilead’s third quarter earnings call, execs announced that the company has hit the brakes on several studies of the autoimmune drug, pending a meeting with the agency next quarter.
But aside from that, the company remains on course with its rapidly expanding oncology ventures, while its traditional antivirals business – especially HIV and hepatitis C – shows signs of...